Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
about
Everolimus in the Treatment of Metastatic Breast CancerToward rapamycin analog (rapalog)-based precision cancer therapyAndrogen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysisJudicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and PerspectivesIdentification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancerPatient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.The latest progress in research on triple negative breast cancer (TNBC): risk factors, possible therapeutic targets and prognostic markersTriple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.mTOR function and therapeutic targeting in breast cancer.Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer.Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.The Effect of Everolimus in an In Vitro Model of Triple Negative Breast Cancer and Osteoclasts.Exceptional durable response to everolimus in a patient with biphenotypic breast cancer harboring an STK11 variant.The therapeutic potential of mTOR inhibitors in breast cancer.Clinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer.Safety of mTOR inhibitors in breast cancer.Rapamycin inhibits prostate cancer cell growth through cyclin D1 and enhances the cytotoxic efficacy of cisplatin.Therapeutic Implications of the Molecular and Immune Landscape of Triple-Negative Breast Cancer.Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancerTriple-negative breast cancer and the potential for targeted therapy
P2860
Q26784920-12B981F8-75D8-4E79-AC45-662696B3694DQ26795606-23B6F4C9-3FB1-4CD2-AD40-5BC67696DB83Q26823419-C0043F3A-8596-4E01-B79C-19C43101D2F6Q28071388-0E173DFD-E93E-4218-B1A1-C9E950740906Q30277772-CE22D87E-7799-4B3A-AC0F-0098F698B3A7Q33739184-3F6EA30B-C298-41D9-80DE-871A0108D130Q34258373-64CCE6B2-A2A4-47C7-BB43-F56EDC293C3BQ37645090-8645018A-0A6B-4EDB-8A9E-4CC8F97EDDC7Q37743486-E38E7DB7-E3EF-470B-8CF5-F525AE9640ADQ38346783-38709F5F-4AB1-496F-90D3-BA24B51E4DD3Q38647802-033A896D-0606-4573-B233-C847A94AEC36Q38733725-4D32682F-FD08-4FE8-98C7-94A0E3CEBB96Q38760757-22A45AC3-719F-4414-AA40-F9AF71739235Q38802412-C3F98BEC-7FD9-4D39-BDC8-EF2F00A61C74Q38825945-98B84F04-5302-41AF-9CF2-DE867F90B94EQ38841039-D8431E0F-E368-4C77-A2D6-D6FAB34780ADQ40970978-1D3777D2-26FB-4C3F-92A8-30FB56D2FBEBQ47638243-E1CF6DA8-E8DA-4EBB-89FF-BD428DFA5D13Q57105411-4D88AADA-F143-40F6-BEF6-A4C5DA8C360EQ57115890-27FE74E7-B01E-42DE-8EA3-13A303BC5C9E
P2860
Phase 2 trial of everolimus and carboplatin combination in patients with triple negative metastatic breast cancer
description
2014 nî lūn-bûn
@nan
2014 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մարտին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Phase 2 trial of everolimus an ...... ative metastatic breast cancer
@ast
Phase 2 trial of everolimus an ...... ative metastatic breast cancer
@en
type
label
Phase 2 trial of everolimus an ...... ative metastatic breast cancer
@ast
Phase 2 trial of everolimus an ...... ative metastatic breast cancer
@en
prefLabel
Phase 2 trial of everolimus an ...... ative metastatic breast cancer
@ast
Phase 2 trial of everolimus an ...... ative metastatic breast cancer
@en
P2093
P2860
P50
P356
P1476
Phase 2 trial of everolimus an ...... ative metastatic breast cancer
@en
P2093
Amy Tiersten
Benson Joseph
Coral Omene
James Speyer
Jasmeet Singh
Julia Smith
Komal Jhaveri
Marlene Meyers
Matthew Volm
Silvia Formenti
P2860
P2888
P356
10.1186/BCR3634
P577
2014-03-31T00:00:00Z
P5875
P6179
1053340096